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Ovarian clear cell carcinoma (OCCC) accounts for a small but significant proportion of all ovarian cancers and is a distinct clinical and
pathological entity. It tends to be associated with poorer response rates to chemotherapy and with a worse prognosis. Little is known
about possible underlying genetic changes. DNA extracted from paraffin-embedded samples of 18 pure OCCC cases was analysed
for genetic imbalances using comparative genomic hybridisation (CGH). All of the 18 cases showed genomic alterations. The mean
number of alterations detected by CGH was 6 (range 1–15) indicating a moderate level of genetic instability. Chromosome deletions
were more common than amplifications. The most prominent change involved chromosome 9 deletions in 10 cases (55%). This
correlates with changes seen in other epithelial ovarian cancers. This deletion was confirmed using microsatellite markers to assess
loss of heterozygosity (LOH) at four separate loci on chromosome 9. The most distinct region of loss detected was around the IFNA
marker at 9p21 with 41% (11 out of 27cases) LOH. Other frequent deletions involved 1p (five out of 18; 28%); 11q (four out of 18;
22%) and 16 (five out of 18; 28%). Amplification was most common at chromosome 3 (six out of 18; 33%); 13q (four out of 18; 22%)
and 15 (three out of 18; 17%). No high-level amplifications were identified. These features may serve as useful prognostic indicators in
the management of OCCC.
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Ovarian malignancy is the fourth leading cause of death from
cancer in women in the UK, and demonstrates an overall 5-year
survival rate of 33% (Gatta et al, 1998). The common histological
subtypes of epithelial ovarian cancer are serous, mucinous and
endometrioid, which together account for more approximately
85% of cases (Clark et al, 2001). Clear cell ovarian carcinoma is a
less common subtype of ovarian cancer and accounts for 5 –10% of
all ovarian malignancies (Kennedy et al, 1989). Although
morphologically distinct, ovarian clear cell carcinoma (OCCC)
remains controversial in terms of pathological characteristics and
grading, response to treatment and overall prognosis.
The identification of clear cell histology has been shown to be an
indicator of poor prognosis in many studies (Sugiyama et al, 2000;
Clark et al, 2001), with an inferior response to platinum-based
chemotherapy (Goff et al, 1996) and an increased incidence of
cancer-related complications, such as thromboembolic disease
(Recio et al, 1996) and malignancy-related hypercalcaemia
(Koshiyama et al, 1999). Although other studies have contested
this view (O’Brien et al, 1993), many clinicians consider clear cell
histology as an indication for chemotherapy in patients with
otherwise low-risk disease (FIGO stage Ia/Ib).
Cytogenetic and molecular analysis of ovarian cancers has
detected a number of structural cytogenetic abnormalities.
Published karyotypic analyses have tended to include epithelial
ovarian cancers of all histological subtypes and have shown
frequent abnormalities of chromosomes 1, 3, 6, 11, 17 and 19, with
less frequent abnormalities of chromosomes 2, 4, 5, 9 and 21
(Gallion et al, 1990; Taetle et al, 1999; Roberts and Tattersall,
1990). The development of improved molecular techniques
including the use of polymorphic genetic markers has provided
more precise ways to identify these genetic abnormalities.
Comparative genomic hybridisation (CGH) is an analytical
technique using a single hybridisation with an equal mixture of
distinct fluorescently labelled normal and tumour DNA that
permits identification of regions of chromosomes that have
undergone either an increase or a decrease in DNA amount,
causing genomic imbalance in the tumour. Thus, it can be used to
examine the entire genome for amplifications and deletions
using extracted tumour DNA (Kallioniemi et al, 1992; Visakorpi,
1995).
Comparative genomic hybridisation analysis has revealed
numerous cytogenetic changes in epithelial ovarian cancers
(Sonoda et al, 1997) with common sites of amplification, in order
of frequency, at 8q, 20q, 3q, 1q, 20p, 9p and 12p along with
deletions at 5q, 9q, 17p, 4q, 16q and 22q. Comparative genomic
hybridisation has detected aberrations that correlate with ovarian
tumour grade including deletions at chromosome 11p and 13q,
and amplifications at 8q and 7p in poorly differentiated tumours as
compared with 12p deletions and 18p amplifications in well- and
moderately differentiated tumours (Kiechle et al, 2001). Some
evidence suggests that the main different histological subtypes
(serous, mucinous and endometrioid) have different copy number
karyotypes, with gains more frequently noted at 10q and 11q in
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endometrioid and serous tumours respectively and at 17q in
mucinous tumours (Tapper et al, 1997).
Previously published cytogenetic analyses of ovarian cancer
have included very few cases with clear cell histology. The aim of
this study was therefore to characterise the genetic alterations of a
cohort of pure clear cell ovarian tumours.
MATERIALS AND METHODS
Tumour samples
Cases of pure clear cell carcinoma of the ovary were identified
from the pathological archives of three specialist cancer hospitals
(St James’s University Hospital, Leeds General Infirmary and Hull
Royal Infirmary). All cases were reviewed and clear cell
morphology confirmed independently by two expert gynaecologi-
cal pathologists (NW and IR). Demographic and survival data were
collected anonymously.
DNA extraction
DNA was extracted from paraffin-embedded samples using
standard techniques (Jackson et al, 1990). Briefly, 10 mm tumour
sections were cut from paraffin wax samples. Sections were de-
waxed in xylene and rehydrated through graded alcohol. Relevant
areas of individual sections were selected manually, dissected and
then digested for 5 days at 371C with proteinase K (0.1 mg ml1,
Sigma, UK) followed by extraction twice with phenol : chloroform :
isoamyl alcohol and once with chloroform : isoamyl alcohol. The
DNA was then precipitated with ethanol, collected by centrifuga-
tion, air-dried and resuspended in sterile distilled water.
Comparative genomic hybridisation
Comparative genomic hybridisation was performed using fluoro-
chrome-conjugated DNAs (Kallioniemi et al, 1992; Visakorpi et al,
1995). In brief, tumour DNA was labelled with Spectrum Green
(Vysis, UK) and normal human genomic placental reference DNA
with Spectrum Red (Vysis, UK) by nick translation. Normal
human lymphocyte metaphase preparations (Vysis, UK) were
denatured at 72–741C for 5 min in a denaturation solution (70%
formamide, 2 SSC, pH 5.3), and dehydrated in an ethanol series
(70, 85, then 100%). A probe mixture comprising 400ng of labelled
tumour DNA, 400ng of labelled reference DNA and 20mg of Cot-1
DNA (Gibco BRL, UK) was denatured at 72–741C for 5 min and
applied to the normal lymphocyte metaphases and cohybridised at
371C for 2 days. Posthybridisation washes were carried out in
0.4 SSC/0.3% (v v1) NP-40 at 72–741C for 2 min, followed by
2 SSC/0.1% (v v1) NP-40 for 2 min at 201C. Slides were air-dried
and counterstained with 4,6-diamidino-2-phenylindole (DAPI) in
Vectashield antifade solution.
Digital image analysis
Hybridised metaphase spread images were visualised using a Zeiss
Axioplan fluorescence microscope. Metaphase images for the three
different colours blue (DAPI), Spectrum Red and Spectrum Green
were collected using a cooled CCD camera (SenSys 1400) and
stored as a three-colour image using the Vysis Quantitative Image
Processing System (QUIPS). The chromosomes were identified
based on their DAPI banding. The green-to-red fluorescence ratio
profiles were automatically determined for each chromosome and
a mean ratio profile combining 5 –10 metaphase spreads was
generated. A ratio of below 0.85 or above 1.15 was taken to indicate
regions of under-representation (losses) or over-representation
(gains), respectively. If the red–green ratio exceeded 1.5 in a small
segment of a chromosome arm, the regions were considered to
represent a high level of DNA amplification.
Loss of heterozygosity
Loss of heterozygosity (LOH) in a total of 27 tumour specimens
was examined with the following microsatellite markers: IFNA
(9p21); D9S104 (9p13); HXB (9q32 –34); D9S64 (9q34). The PCR
reaction mixture contained 12.5 pmol of each primer, one of which
was fluorescently labelled, 0.75 U Taq DNA polymerase (Promega,
UK), 1.5 mM MgCl2, 200 mM each of dATP, dCTP, dTTP, dGTP and
50 ng of sample DNA in a 20 ml reaction volume. PCR amplification
was performed in a thermal-cycler (Perkin-Elmer, UK). The
conditions for amplification were 951C for 5 min, then 40 cycles
of 951 for 30 s, 581 for 45 s, and 721C for 45 s with a final extension
at 721C for 5 min.The PCR products were denatured and run on a
6% polyacrylamide denaturing gel in 1Tris Boric Acid (TBE)
buffer on a Model 377 Applied Biosystems automated fluorescent
DNA sequencer, using a four-colour detection system. One
microlitre from each PCR was combined with 4 ml formamide
and 0.5 ml of a fluorescent size marker solution (Applied
Biosystems, UK). This mixture was denatured for 3 min at 901C
after which 5 ml was loaded into each well on the prewarmed gel.
The gel was run for 4 h at 30 W and 501C.
The fluorescent gel data collected during the run were analysed
using the Genescan Analysis program (ABI) at the end of the run.
Allelic imbalance indicative of LOH was scored when there was
more than 50% loss of intensity of one allele in the tumour sample
compared to the matched allele from normal tissue (Cawkwell et al,
1993).
RESULTS
Thirty three cases of OCCC, presenting between 1976 and 1999,
were identified from the pathological records of three institutions.
Comparative genomic hybridisation was performed on 18 of these
cases (case numbers 1–18). Twelve of the 18 CGH cases had
sufficient tumour and normal material for confirmatory LOH
markers also to be analysed. Loss of hetrozygosity marker analysis
was also performed on an additional 15 cases (case numbers 19–
33) for which paired tumour and normal samples could be
identified. In total, LOH was performed on 27 of the 33 OCCC cases.
Clinical results
The median age at diagnosis was 57 years (range 37–84). There
were 20 (61%) FIGO stage I, one (3%) FIGO stage II, nine (27%)
FIGO stage III and three (9%) FIGO stage IV cases. The median
actuarial overall survival for all 33 cases was 3.7 years with a 5 year
overall survival rate of 45% (95% CI 28–62%).
CGH results
Genomic imbalances were detected in all 18 cases of OCCC
examined by CGH (Figure 1, Table 1). Chromosomal losses were
found more frequently than chromosomal gains, with a mean
number of CGH changes (gains and losses) per case of 6 (range 1–
15). No high-level amplifications were identified at the 1.5
threshold. Chromosome 9 was the most common site for genetic
abnormalities with 10 of the 18 (55%) cases showing deletion of 9p
and/or 9q frequently altered, again showing a higher prevalence of
losses than gains. Other common deletions included chromosome
1p (five cases, 28%), chromosome 11q (four cases, 22%) and
chromosome 16p/q (five cases, 28%). The most common sites of
amplification were on chromosome 3 (six cases, 33%) and
chromosome 13q (four cases, 22%).
LOH results
In view of the high rate of loss on chromosome 9, LOH marker
analysis was performed as described. Six cases (case numbers 1, 2,
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3, 4, 10 and 11) that had loss seen on chromosome 9 with CGH had
confirmatory LOH studies carried out. Loss of heterozygosity was
identified in at least one locus on chromosome 9 in all of these six
cases. In total, combining all 27 LOH cases, LOH was observed in
11 cases (41%) at IFNA marker (9p21), seven cases (26%) at
D9S104 (9p13), nine cases (33%) at HXB (9q32–34) and 10 cases
(37%) at D9S64 (9q34) (Figure 2).
DISCUSSION
This study has assessed the cytogenetic abnormalities in a cohort
of ovarian cancers with pure clear cell histology. Comparative
genomic hybridisation performed on 18 cases identified frequent
deletions of chromosome 9p, 1p, 11q and 16p/q and amplifications
of 3 and13q.
13 15 1917
2 116 124 8 1031 5 7 9
14 16 18 21 Y20 22 X
Figure 1 Schematic representation of the chromosomal imbalances detected by CGH in 18 cases. Red vertical lines on the left-hand side represent
chromosome deletion. Green vertical lines on the right-hand side represent chromosome amplification. Each line represents genetic aberrations in one case.
Table 1 Comparative genomic hybridisation findings in 18 clear cell ovarian carcinoma cases
Case Stage CGH results
1 3c +10p14, +16p13, +18p, +19q13.3, +20p12 8q23–24.3, 9
2 1c +6, +8p22, +12p12, +13, +15p, +22, +X 1q32, 7p13q22, 9q21, 14
3 1c +7q21–31, +8cterp21.3 2p22–24, 3q26.3, 5p14, 5q31–34, 9q31–34, 10, 11q23, 12p12, 12q24.2, 15q, 16p12,
16q22, 19q13.1, 20q12
4 1c +3q, +5q11.2–21 –9q21, 10p12, 11q23, 16p12q22, 22pter –q12
5 3b +4q12–24 8p21, 11q, 14q, 17p
6 3b +4q12–24, +7q21–36, +8p12–qter, +10q, +13q21, 9q, 10p13, 11q23, 16p12–q13
7 1a +3p25, +3p12, +15pter –q21 1pter–32
8 1c +3, +15p 9, 7q, 13q14–32
9 3c +3p12
10 1a +13p13–q14, +14p13–q13, +17, +18p 3q13.3–26, 9, 10q23–25, 19q13.2, 20q11.2–13.1
11 1a +1p22, +4, +12, +13q28, +18 1p36.1, 9q, 17, 19p, 22pter–q12
12 1c +3p26–24, +9q33, +17q24
13 1a 19p13.1–q13.2
14 1c 1p31–pter, 5q21–33, 14q21–31
15 2a +9q12 1p33–35, 5p14, 12q24.1
16 4 1, 7, 9p21–q33, 10q22–25, 15cter –q25, 16, 20p, 20q12, 22
17 3c 7p14–pter, Xq24–qter
18 3c 6, -8, 9q21–33
CGH in ovarian clear cell carcinoma
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Analysis of the three main histological ovarian subtypes (serous,
mucinous and endometrioid) has demonstrated distinct karyo-
types with gains at 17q more frequent in mucinous tumours with
gains at 1q, 10q and 11q seen more commonly in serous and
endometrioid tumours (Tapper et al, 1997). However, CGH
analysis of fallopian tube carcinoma has demonstrated similarities
with serous carcinoma of both uterus and ovary (Pere et al, 1998).
Our results suggest that the pattern of genomic alterations found in
clear cell ovarian tumours is distinct from that seen in other
ovarian histological subtypes. A recent analysis of ovarian cancer
using oligonucleotide microarrays has demonstrated distinct
patterns of gene expression for the different morphological
subtypes. In clear cell tumours, 73 genes, with a two- to 29-fold
increase in expression, were identified which distinguished it from
other ovarian subtypes (Schwartz et al, 2002).
The cytogenetics of 12 cases of clear cell ovarian carcinoma
assessed by CGH has been reported by Suehiro et al (2000). This
Japanese study, which included eight cases of FIGO stage I disease,
demonstrated amplification of chromosome 8q in eight cases
(67%). Increased copy number was also frequently identified on
chromosomes 17q and 20q; reduced copy number of 19p was also
identified; chromosome 9 deletions were only seen in two cases
(17%). No LOH analysis was performed either to confirm or
further define these changes.
These results are distinct to those obtained in the current study,
where amplification of chromosome 8 was infrequent and deletion
of chromosome 9p and q was common. The reason for these
differences is not clear. However, in many Japanese studies the
incidence of clear cell histology in epithelial ovarian carcinoma is
as high as 15.3% (Sugiyama et al, 2000). This differs significantly
from an incidence of approximately 5% seen in American or
European studies (Omura et al, 1991; O’Brien et al, 1993). It is not
clear whether this reflects differences in the diagnostic criteria
used to define the clear cell phenotype in Japan, or differences in
the molecular genetics of ovarian cancer in Japanese women. Other
CGH studies of ovarian cancer of all histological subtypes have
identified deletions of chromosome 9p; a study of 24 cases of grade
1 or 2 ovarian cancers reported 9p loss in six cases (25%; (Tapper
et al, 1997)). A larger study of 106 cases of all histological grades
identified 9p loss in 41% of patients (Kiechle et al, 2001).
The LOH analysis of chromosome 9 performed herein,
confirmed the CGH results obtained in this study and was
consistent with other published data (Chenevix-Trench et al,
1994). A detailed analysis of chromosome 9 in 33 ovarian tumours
of various grades and stages detected LOH in 26 cases (79%) and
proposed three specific regions of deletion – one at 9p21 and two
on 9q; one proximal, one distal (Devlin et al, 1996). During the last
few years, these three regions of deletion have been examined in
detail in attempts to identify tumour suppressor genes whose
function is lost in a variety of ovarian cancers.
The locus at 9p21, deleted in 11 of the 20 informative cases
(55%) in this study, includes the cyclin-dependent kinase inhibitor
2 (CDKN2) locus, a region now known to encode the proteins
CDKN2A/p16(INK4A), CDKN2B/p15(INK4B) and an alternative
reading frame of CDKN2A, p14ARF (Kamb et al, 1994; Stott et al,
1998). These three proteins act as tumour suppressor genes
through the two central growth control pathways, which act upon
Rb and p53 (Saegusa et al, 2001). Deletion or inactivation of genes
within this region is a frequent cytogenetic abnormality in other
malignancies such as melanoma (Kamb et al, 1994), bladder cancer
(Cairns et al, 1995) and renal cancer (Schraml et al, 2001). In the
past, OCCC has been confused with metastatic renal cell carcinoma
(Young and Hart, 1992) and it is interesting to note that
chromosome 9 loss has also been found in renal clear cell tumour
with 33% having partial or complete deletion of chromosome 9
(Cairns et al, 1995).
The data we have obtained suggest a role for one or more of the
gene products from this locus in the molecular pathogenesis of
clear cell ovarian carcinoma. The expression of CDKN2A/
p16(INK4A) in ovarian carcinoma has been assessed in a number
of studies with conflicting results. P16 overexpression has been
reported in 22 of 24 (90%) high-stage malignant ovarian tumours
(Shigemasa et al, 1997), whereas other reports suggest a
correlation between p16 underexpression and low-grade ovarian
tumours; 22 out of 60 (37%) (Fujita et al, 1997).
The deletions seen within chromosome 9q by both CGH and
LOH in our study may also imply a role for alternative tumour
suppressor genes in the molecular pathogenesis of clear cell
ovarian carcinoma. The distal locus on 9q includes two genes with
potential roles as tumour suppressor genes in ovarian cancer; the
TSC1 gene at 9q34 (Miloloza et al, 2000) and the DBCCR1 gene at
9q32–33 (Habuchi et al, 1998). The specific roles of these genes in
the pathogenesis and prognosis of ovarian cancer have not
previously been assessed.
The other frequent genetic abnormalities seen in this study
include deletion on chromosome 16p and 16q and amplification of
chromosome 3p and 3q. Allele loss on 16q has been connected with
progression of some cancer types, including breast and lung (Lee,
1996; Sato et al, 1998). 16q deletions were observed in 14 of 21
(67%) high-grade epithelial ovarian tumours (Kawakami et al,
1999). Candidate genes that map to this region include CDH13 (H-
cadherin; 16q24). This gene belongs to the family of cell adhesion
molecules of which E-cadherin is a well-recognised tumour
suppressor gene in gastric cancer (Becker et al, 1994). Copy
number increases of chromosome 3q in ovarian carcinomas have
previously been reported (Arnold et al, 1996; Sonoda et al, 1997)
Case number
CGH cases  with LOH LOH only cases 
1 2 3 4 7 9 10 11 12 14 15 17 19 20 21 22 23 24 25 25 27 28 29 30 31 32 33
IFNA
9p21 
D9S 104
9p13 
HXB  
9q32−34 
D9S 64 
9q34
 = loss;  = retained; no symbol = non-informative 
IFNA
D9S104 
D9S64 
HXB
110
116
2
3
4
18
16
8
∆
∆ ∆ ∆
∆ ∆
∆
∆ ∆ ∆
∆∆
∆∆
∆ ∆∆∆∆
∆∆
∆ ∆∆
∆ ∆
∆ ∆
∆
∆∆∆
∆ ∆ ∆ ∆
∆
∆ ∆ ∆ ∆
Figure 2 Chromosome 9 LOH marker results with chromosome 9 ideogram. Loss of heterozygosity was performed on a total of 27 cases. The case
numbers on the left represent LOH cases for which CGH was also performed (see Table 1). The remaining cases (numbered 1–15) had LOH alone
performed.
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and mapped to a region at 3q26 containing PIK3CA (Shayesteh
et al, 1999). Furthermore, upregulation of this gene has been seen
in 36% of malignant, mostly serous, high-grade ovarian carcino-
mas (Sonoda et al, 1997). PIK3CA encodes a subunit of a
phosphatidylinositol 3-kinase involved in kinase-mediated cell
signalling (Rodriguez-Viciana et al, 1996). Other published work
has also found that copy number alterations in ovarian cancer
correlates to histological tumour grade with an overall increase in
DNA sequence copy number abnormalities seen in high-grade
tumours as opposed to low-grade tumours (Iwabuchi et al, 1995).
Specifically, 3q alterations were reported in high-grade tumour
cases with an increased copy number on 3q25–26 found in 13 out
of 26 cases (50%).
The cytogenetic abnormalities detected by the present study
reflect many of those previously identified in other histological
subtypes of ovarian cancer (Sonoda et al, 1997; Tapper et al, 1997).
No genetic change unique to the clear cell histology was identified.
Further characterisation of candidate genes within the regions of
deletion/amplification is underway.
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